The acquisition reflects Roche's strategy to grow through targeted deals to enhance its pipeline in specific disease areas like obesity and diabetes.
Miler M, ivanovi J, Ajdanovi V, Milenkovic D, Cesar T, Filipovi MR, Miloevi V
Until more research is available, the use of these drugs in T1D should be done carefully, with a thorough discussion with patients about potential risks and benefits of this approach
It is about what happens when body image, social media, and gray market pharmacology collide
Hewage (2006) NMR and alanine scan studies of glucose-dependent insulinotropic peptide in water
Safety and efficacy of combination therapy with semaglutide, Cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial